Regular Article

British Journal of Cancer (2001) 84, 42–47. doi:10.1054/bjoc.2000.1543 www.bjcancer.com
Published online 3 January 2001

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

M M Malingré1,2, J H Beijnen1,2,4, H Rosing2, F J Koopman2, R C Jewell3, E M Paul3, W W Ten Bokkel Huinink1 and J H M Schellens1,4

  1. 1Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
  2. 2Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, EC, 1066, The Netherlands
  3. 3Glaxo Wellcome, Research Triangle Park, Five Moore Drive, NC, 27709, USA
  4. 4Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, Utrecht, CA, 3584, The Netherlands

Received 22 May 2000; Revised 31 August 2000; Accepted 13 September 2000.

Top

Abstract

Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocker cyclosporin A (CsA). Now we tested the potent alternative orally applicable non-immunosuppressive P-gp blocker GF120918. Six patients received one course of oral paclitaxel of 120 mg/m2 in combination with 1000 mg oral GF120918 (GG918, GW0918). Patients received intravenous (i.v.) paclitaxel 175 mg/m2 as a 3-hour infusion during subsequent courses. The mean area under the plasma concentration–time curve (AUC) of paclitaxel after oral drug administration in combination with GF120918 was 3.27 plusminus 1.67 muM.h. In our previously performed study of 120 mg/m2 oral paclitaxel in combination with CsA the mean AUC of paclitaxel was 2.55 plusminus 2.29 muM.h. After i.v. administration of paclitaxel the mean AUC was 15.92 plusminus 2.46 muM.h. The oral combination of paclitaxel with GF120918 was well tolerated. The increase in systemic exposure to paclitaxel in combination with GF120918 is of the same magnitude as in combination with CsA. GF120918 is a good and safe alternative for CsA and may enable chronic oral therapy with paclitaxel. © 2001 Cancer Research Campaign

Keywords:

paclitaxel, oral administration, bioavailability, P-glycoprotein, GF120918

Top

References

  1. Dye D and Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. BMJ 280: 1353 | PubMed | ChemPort |
  2. Ferry D, Moore M, Bartlett NL, Fyfe D, Oza A, Fracasso PM, Kersey K, Wissel PS, Jewell RC and Paul EM (1998) Phase I and pharmacokinetic study targeting a 500 ng/mL plasma concentration of the potent multidrug resistance modulator GF120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 240a
  3. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G and Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13: 180–190 | PubMed | ISI | ChemPort |
  4. Gibaldi M and Perrier D (1982) Noncompartmental analysis based on statistical moment theory. Gibaldi M, Perrier D (eds) Pharmacokinetics, New York, Marcel Dekker. pp. 409–417
  5. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994) Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026–4035 | PubMed | ISI | ChemPort |
  6. Hyafil F, Vergely C, Du Vignaud P and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595–4602 | PubMed | ISI | ChemPort |
  7. Huizing MT, Keung ACF, Rosing H, Van der Kuij V, Ten Bokkel Huinink WW, Mandjes I, Dubbelman AC, Pinedo HM and Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2117–2135
  8. Huizing MT, Van Warmerdam LJC, Rosing H, Ten Bokkel Huinink WW, Stewart MB, Pinedo HM and Beijnen JH (1995a) Limited sampling strategies for investigating paclitaxel pharmacokinetics in patients receiving 175 mg/m2as a 3-hour infusion. Clin Drug Invest 9: 344–353
  9. Huizing MT, Sparreboom A, Rosing H, Van Tellingen O, Pinedo HM and Beijnen JH (1995b) Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B 674: 261–268
  10. Huizing MT, Giaccone G, Van Warmerdam LJC, Rosing H, Bakker PJM, Vermorken JB, Postmus PE, Van Zandwijk N, Koolen MGJ, Ten Bokkel Huinink WW, Van der Vijgh WJF, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CHN and Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: A European Cancer Centre (ECC) trial. J Clin Oncol 15: 317–329 | PubMed | ChemPort |
  11. Malingré MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, Van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J and Schellens JHM (2000) Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18: 2468–2475 | PubMed | ChemPort |
  12. Meerum Terwogt JM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H and Schellens JHM (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285 | Article | PubMed | ChemPort |
  13. Meerum Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M and Schellens JHM (1999) Co-administration of cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5: 3379–3384 | PubMed | ChemPort |
  14. Natale RB (1998) Experience with new chemotherapeutic agents in non-small cell lung cancer. Chest 113: 32S–39S
  15. National Cancer Institute, Division of Cancer TreatmentBethesda MD (1988). Guidelines for Reporting of Adverse Drug Reactions,
  16. Ohtsu T, Yasutsuna S, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y and Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599–606 | PubMed | ISI | ChemPort |
  17. Planting A, Van der Gaast A, Sparreboom A, Van der Burg MEL, De Boer M, Wissel PS, Jewell RC, Paul EM and Verweij J (1998) Phase I and pharmacokinetic study targeting a 100 ng/mL plasma concentration of the potent multidrug resistance modulator GF 120918 with doxorubicin in patients with advanced solid tumours. Proc Am Soc Clin Oncol 17: 199a
  18. Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1004–1014 | Article | PubMed | ISI | ChemPort |
  19. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161–170 | Article | PubMed | ISI | ChemPort |
  20. Shet MS, Fisher CW, Holmans PL and Estabrook RW (1993) Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 90: 11748–11752 | PubMed | ChemPort |
  21. Sparreboom A, Van Tellingen O, Nooijen WJ and Beijnen JH (1996a) Tissue distribution, metabolism and excretion of paclitaxel in mice. Anti-Cancer Drugs 7: 78–86
  22. Sparreboom A, Van Tellingen O, Nooijen WJ and Beijnen JH (1996b) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112–2115 | PubMed | ChemPort |
  23. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH and Van Tellingen O (1997) Limited oral bioavailability and active epithelial secretion of paclitaxel caused by P-glycoprotein in the intetestine. Proc Natl Acad Sci USA 94: 2031–2035 | Article | PubMed | ChemPort |
  24. Sparreboom A, Verweij J, Van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, De Vos AI, Nooter K, Stoter G and Gianni L (1998) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937–1942 | PubMed | ChemPort |
  25. Van Asperen J, Van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ and Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice co-treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76: 1181–1183 | PubMed | ChemPort |
  26. Van Asperen J, Van Tellingen O and Beijnen JH (1998a) The pharmacological role of P-glycoprotein in the intestinal epithelium. Phramacol Res 37: 429–435
  27. Van Asperen J, Van Tellingen O, Van der Valk MA, Rozenhart M and Beijnen JH (1996b) Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4: 2293–2297
  28. Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ and Beijnen JH (1999) Cremophor EL causes (pseudo-)non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335 | Article | PubMed | ChemPort |
  29. Van Tellingen O, Bardelmeijer HA, Rosing H, Brouwer KR, Nooijen WJ and Beijnen JH (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Proc Am Assoc Cancer Res 41: 673
  30. Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y and Tsuruo T (1996) Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anti Cancer Drugs 7: 825–833
  31. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J and Woodcock D (1993) Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst 85: 1685–1690 | Article | PubMed | ChemPort |
  32. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD and Layland-Jones B (1990) Hypersensitive reactions from Taxol. J Clin Oncol 8: 1263–1268 | PubMed | ISI | ChemPort |
  33. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B and Bertoncello I (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199–4203 | PubMed | ChemPort |
  34. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS and Wissel PS (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7–12 | PubMed | ISI | ChemPort |
  35. World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment, Geneva, Switzerland